Triodos Investment Management BV Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Triodos Investment Management BV trimmed its position in Edwards Lifesciences Co. (NYSE:EWFree Report) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 368,258 shares of the medical research company’s stock after selling 6,000 shares during the period. Edwards Lifesciences makes up about 2.7% of Triodos Investment Management BV’s holdings, making the stock its 16th biggest position. Triodos Investment Management BV owned approximately 0.06% of Edwards Lifesciences worth $28,080,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of EW. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $34,000. Operose Advisors LLC grew its stake in shares of Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares during the period. SRS Capital Advisors Inc. increased its holdings in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $52,000. Finally, ORG Partners LLC purchased a new stake in Edwards Lifesciences during the third quarter worth about $66,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 2.1 %

Shares of EW traded up $1.76 during mid-day trading on Tuesday, reaching $86.46. The company had a trading volume of 2,119,569 shares, compared to its average volume of 3,662,030. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a fifty day simple moving average of $90.06 and a 200-day simple moving average of $80.21. The stock has a market cap of $52.10 billion, a price-to-earnings ratio of 37.21, a price-to-earnings-growth ratio of 3.65 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Friday, May 10th. The shares were sold at an average price of $87.81, for a total transaction of $439,050.00. Following the transaction, the vice president now owns 47,750 shares in the company, valued at approximately $4,192,927.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total value of $73,359.20. Following the transaction, the vice president now owns 23,890 shares in the company, valued at $2,044,984. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $87.81, for a total value of $439,050.00. Following the sale, the vice president now owns 47,750 shares of the company’s stock, valued at approximately $4,192,927.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 213,340 shares of company stock valued at $18,816,952. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Royal Bank of Canada increased their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Piper Sandler lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Wells Fargo & Company raised their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Barclays lifted their target price on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $93.88.

Check Out Our Latest Stock Analysis on EW

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.